Vitamin E Serum Levels and Bleeding Risk in Patients Receiving Oral Anticoagulant Therapy: a Retrospective Cohort Study

Background Hemorrhagic risk assessment is a crucial issue in patients with nonvalvular atrial fibrillation (NVAF) who are receiving oral anticoagulant therapy (OAT). Our aim was to analyze the relationship between vitamin E, which possesses anticoagulant properties, and bleeding events in NVAF patients. Methods and Results In this retrospective observational study we analyzed baseline serum cholesterol‐adjusted vitamin E (vit E/chol) levels in 566 consecutive patients (59% males, mean age 73.6 years) receiving OAT followed up for a mean time of 22 months. Mean time in therapeutic INR range (TTR) was 64%. The overall incidence rate of any bleeding event was 9.2/100 person‐years. Compared to patients who did not bleed, those who experienced bleeding events (n=92, 73 minor and 15 major bleedings and 4 cerebral hemorrhages according to International Society on Thrombosis and Haemostasis [ISTH] ) classification) showed a significant difference for history of coronary heart disease (P=0.039), HAS‐BLED score (P=0.002), and vit E/chol levels (P<0.001). Higher vit E/chol serum levels were found in patients who bled compared to those who did not (5.27±1.93 versus 4.48±1.97 μmol/cholesterol; P<0.001), with a progressive increase from minor (5.16±1.91 μmol/mmol cholesterol, P=0.006) to major bleedings (5.72±2.0 μmol/mmol cholesterol, P=0.008). A Cox proportional hazard model demonstrated that serum vit E/chol quartiles (global P=0.0189) and HAS‐BLED scores (P=0.005) predicted bleeding events. Conclusions In a NVAF population being treated with warfarin, serum vitamin E predicted hemorrhagic events. Further study is necessary to see if the relationship between serum levels of vitamin E and bleeding is still maintained with the use of new anticoagulants. Clinical Trial Registration URL: ClinicalTrials.gov. Unique identifier NCT01882114.

[1]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[2]  A. Farcomeni,et al.  Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. , 2013, International journal of cardiology.

[3]  A. Young,et al.  Anticoagulant activity of select dietary supplements. , 2012, Nutrition reviews.

[4]  Christophe Tzourio,et al.  Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials , 2010, BMJ : British Medical Journal.

[5]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[6]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[7]  J. Manson,et al.  Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. , 2008, JAMA.

[8]  M. Traber.  Vitamin E and K interactions--a 50-year-old problem. , 2008, Nutrition reviews.

[9]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[10]  J. Manson,et al.  A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. , 2007, Archives of internal medicine.

[11]  B. Williams.  The year in hypertension. , 2006, Journal of the American College of Cardiology.

[12]  J. Coombes,et al.  Vitamin E and a-Lipoic Acid Supplementation Increase Bleeding Tendency via an Intrinsic Coagulation Pathway , 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[13]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[14]  J. Manson,et al.  Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.

[15]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[16]  Roberto Pastor-Barriuso,et al.  Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.

[17]  M. Martínez-González,et al.  Development of a short dietary intake questionnaire for the quantitative estimation of adherence to a cardioprotective Mediterranean diet , 2004, European Journal of Clinical Nutrition.

[18]  S. Booth,et al.  Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status. , 2004, The American journal of clinical nutrition.

[19]  D. Singer,et al.  The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. , 2004, Archives of internal medicine.

[20]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.

[21]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[22]  Yuchiao Chang,et al.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.

[23]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[24]  M. Roncaglioni.  Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice , 2001, The Lancet.

[25]  M. Traber,et al.  Measurement of lipid-soluble vitamins-further adjustment needed? , 2000, The Lancet.

[26]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[27]  Edward Groth,et al.  Facts and hypotheses , 1999, Nature Biotechnology.

[28]  P. Gazzaniga,et al.  Vitamin E inhibits collagen-induced platelet activation by blunting hydrogen peroxide. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[29]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[30]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[31]  B. Furie,et al.  Vitamin K-Dependent Biosynthesis of γ-Carboxyglutamic Acid , 1999 .

[32]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[33]  J. Loscalzo,et al.  alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. , 1996, Circulation.

[34]  Vittorio Pengo,et al.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) , 1996, The Lancet.

[35]  M. Brown,et al.  A Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: The Cambridge Heart Antioxidant Study (CHAOS) , 1996 .

[36]  P. Dowd,et al.  On the mechanism of the anticlotting action of vitamin E quinone. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Hart,et al.  Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. , 1995, Stroke.

[38]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[39]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[40]  J. G. Bieri,et al.  Simultaneous determination of alpha-tocopherol and retinol in plasma or red cells by high pressure liquid chromatography. , 1979, The American journal of clinical nutrition.

[41]  Douglas S. Lee,et al.  Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. , 2012, The Canadian journal of cardiology.

[42]  P. Kirchhof,et al.  Bleeding risk assessment and management in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[43]  William T. Abraham,et al.  Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .

[44]  J. Alpert,et al.  Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .

[45]  P. Gazzaniga,et al.  Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets. , 2002, Haematologica.

[46]  D. Albanes,et al.  Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[47]  D. Albanes,et al.  Controlled Trial of α-Tocopherol and β-Carotene Supplements on Stroke Incidence and Mortality in Male Smokers , 2000 .

[48]  G. FitzGerald,et al.  HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Vitamin E Reduces Monocyte Tissue Factor Expression in Cirrhotic Patients , 1999 .